Fresh analysis indicates that patients who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who end traditional lifestyle programs.
Findings released in a major medical journal demonstrates that while obese people can lose substantial amounts of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month once they quit.
"People using these drugs must be informed of the danger of rapid weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to starting mass in about 18 months.
Comparing Approaches
The analysis, which looked at 37 of trials involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
The team note that individuals who lose weight through diet and exercise typically have a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Doctors suggest the way of the jabs explains the amplified regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 levels several times higher than normal may cause the body to produce less of its endogenous hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this GLP-1 'fix' results in hunger is no longer kept in check, making binge eating a significant risk."
A Chronic Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the treatment should be considered ongoing.
This opinion is echoed by drug manufacturers, who state that the findings "highlight the persistent nature of obesity," comparing it to managing diseases like diabetes.
User Testimonies
People who have come off the medication describe a intense return of cravings.
"It was like something flipping and you're instantly starving," recalled one woman.
The struggle is compounded if patients have not developed sustainable dietary or behavioural changes during treatment.
Widespread Use
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and maintained weight loss hinges on integrated behavioural management.
